Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.61 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MB | P02144 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455948 | 0.95 | CYP17A1 (0.54) | CYP17A1PSMB8MAP4K4MIFMAPT | |
| SCHEMBL437131 | 0.95 | CYP17A1 (0.54) | CYP17A1PSMB8MAP4K4MIFMAPT | |
| SCHEMBL20865536 | 0.93 | CYP17A1 (0.68) | CYP17A1PSMB8MAP4K4CA12CA1 | |
| SCHEMBL13055402 | 0.87 | CYP17A1 (0.59) | CYP17A1PSMB8MAP4K4CA12CA1 | |
| SCHEMBL18570243 | 0.86 | CYP17A1 (0.61) | CYP17A1PSMB8MAP4K4MAPTMEN1 | |
| SCHEMBL206442 | 0.85 | CYP17A1 (0.59) | CYP17A1PSMB8MAP4K4MEN1KMT2A | |
| SCHEMBL20865538 | 0.85 | CYP17A1 (0.59) | CYP17A1PSMB8MAP4K4CD274NAMPT | |
| SCHEMBL3785153 | 0.85 | CYP17A1 (0.59) | CYP17A1PSMB8MAP4K4MAPTMEN1 | |
| SCHEMBL22295001 | 0.83 | CYP17A1 (0.58) | CYP17A1PSMB8MAP4K4CA12CA1 | |
| SCHEMBL4759920 | 0.83 | CYP17A1 (0.79) | CYP17A1PSMB8MAP4K4CD274NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617795-B2 | Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators | ASTRAZENECA AB (SE) | 2026-05-05 | — | — | US | disclosed |
| CN-119735594-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119684299-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119684300-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-115298182-B | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024250537-A1 | DIAMINE COMPOUND, LIQUID CRYSTAL ALIGNMENT AGENT, AND LIQUID CRYSTAL ALIGNMENT FILM | 惠州华星光电显示有限公司 | 2024-12-12 | — | — | WO | disclosed |
| EP-4103566-B1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| EP-4103566-B1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| US-20230151013-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151013-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151013-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-05-18 | — | — | US | disclosed |
| EP-4103566-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | AstraZeneca AB (SE) | 2022-12-21 | — | — | EP | disclosed |
| CN-115298182-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021180952-A9 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021180952-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 | ASTRAZENECA AB (SE) | 2021-09-16 | — | — | WO | disclosed |
| US-7534894-B2 | Biphenyloxy-acids | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1667959-A1 | BIPHENYLOXY-ACIDS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060020003-A1 | Biphenyloxy-acids | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2005030702-A1 | BIPHENYLOXY-ACIDS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020003-A1 | Biphenyloxy-acids | AHR, ARNT, NR1H4 | CYP17A1 194/4885PSMB8 4151/4885MAP4K4 3802/4885 |
| US-20230151013-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | KCNC1, KCNJ11, KCNJ1 | CYP17A1 3632/4885PSMB8 4451/4885MAP4K4 915/4885 |
| US-12617795-B2 | Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators | KCNC1, TRPC6, KCNH2 | CYP17A1 2379/4885PSMB8 4140/4885MAP4K4 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.